[3P-0904（3AT26-05）] Analysis of genes which showed synthetic lethal phenotype with BAP1 mutations in malignant mesothelioma cells.

〇Yuko Murakami-Tonami¹, Miki Amano^1,2, Anna Ogiso^1,2, Shinichi Kiyonari³, Tomohiro Akashi⁴, Nor Kaneda², Kenji Kadomatsu³, Hiroshi Murakami⁵, Yoshitaka Sekido¹ (1.Div. Mol. Oncol., Aichi Cancer Cntr Res. Inst., 2.Lab. Anal. Neurobiol., Fac. Pharm., Meijo Univ., 3.Dept. Mol. Biol., Nagoya Univ. Grad. Sch. Med., 4.Div. Omics Analys., Nagoya Univ. Grad. Sch. Med., 5.Lab. Mol. Cell Genet., Fac. Sci. Eng., Chuo Univ.)

ConBio2017

[3P-0905（3AT26-06）] Aberrant Wnt signaling and tumorigenesis by RNF43 mutation in animal models

〇Tadasuke Tsukiyama¹, Jihoon Kim², Takamasa Masuda⁴, Sayuri Terai¹, Hidehisa Takahashi¹, Tohru Ishitani^3,4, Bon-Kyoug Koo², Shigetsugu Hatakeyama¹ (1.Dept. of Biochem., Fac. of Med., Hokkaido Univ., 2.Stem Cell Inst, Univ. of Canbridge, 3.Integ. Sig. Sys., Inst. of Mol. Cell. Reg., Gunma Univ., 4.Dev. of Cell. Reg. Sys., Med. Inst. of Bioreg., Kyushu Univ.)

ConBio2017

[3P-0906（3AT26-07）] Prolonged hypoxia downregulates the expression of pyruvate dehydrogenase PDH-E1β and induces glycolytic metabolism in cancer cells.

Ryo Yonashiro¹, Masaki Wake², Norihiko Takeda², 〇Koh Nakayama¹ (1.Oxygen Biol., Med. Res. Inst., TMDU, 2.Grad. Sch. of Med., Univ. of Tokyo)

ConBio2017

[3P-0907（3AT26-08）] Analysis of synthetic lethality with paclitaxel in BRCA2-deficient cells

〇Shota Yamada¹, Miho Takaoka¹, Akira Nakanishi¹, Yoshio Miki^1,2 (1.Dept. Mol. Genet., Tokyo Med&Dent. Univ., Med. Res., 2.Dept. Mol. Diagnosis, JFCR, The Cancer Inst)

ConBio2017

[3P-0908（3AT26-09）] Prostate cancer-derived extracellular vesicles promote formation of filopodia in osteoclasts

〇Fumihiko Urabe^1,2, Nobuyoshi Kosaka¹, Yusuke Yoshioka¹, Fumitaka Takeshita³, Shin Egawa², Takahiro Ochiya¹ (1.Div. Mol. Cell. Med, Natl. Cancer Ctr. Res. Inst, 2.Dept. Urology, Jikei Univ., Sch. Med., 3.FIOC, Natl. Cancer Ctr. Res. Inst)

ConBio2017

[3P-0909（3AT26-10）] Identification of markers to predict response of HER2-positive breast cancer to trastuzumab by multi-omics approach

〇Satoshi Yamashita¹, Naoko Hattori¹, Satoshi Fujii², Reiko Nagano¹, Kana Kimura¹, Hirohumi Mukai³, Toshikazu Ushijima¹ (1.Div. Epigenomics, Natl Cancer Ctr Res Inst, 2.EPOC, Natl Cancer Ctr , 3.East Hosp, Natl Cancer Ctr)

ConBio2017

[3P-0910（3AT26-11）] Abcg2-induced MDS/AML Cells Perturb Bone Formation by Inhibiting Osteoblastic Differentiation of Bone Marrow Mesenchymal Stem Cells

〇Yasutaka Hayashi¹, Kimihito Cojin Kawabata^1,2, Yasufumi Uehara³, Yosuke Tanaka¹, Yuya Kunisaki⁴, Susumu Goyama¹, Fumio Arai⁴, Toshio Kitamura¹ (1.Cellular Therapy, IMSUT, Univ. of Tokyo , 2.Hematology-Medical Oncology, Weill Cornell Medicine, 3.Dept. of Medicine and Biosystemic Science, Kyushu Univ., 4.Dept. of Cancer Stem Cell Research, Kyushu Univ.)

ConBio2017

[3P-0911（3AT26-12）] Disruption of FBXL5-mediated cellular iron homeostasis promotes liver carcinogenesis

〇Yoshiharu Muto¹, Masaaki Nishiyama¹, Toshiro Moroishi¹, Keiichi Nakayama¹ (1.Med. Insti. of Bioreg., Univ. of Kyushu)

ConBio2017

[3P-0912（3AT26-13）] NRF2 activation induces cancer-related inflammation and malignancy of Kras-induced lung tumors

〇Makiko Hayashi¹, Ayumi Kuga¹, Hozumi Motohashi³, Mikiko Suzuki², Masayuki Yamamoto¹ (1.Dept. of Med. Biochem., Grad. Sch. of Med., Tohoku Univ., 2.RI Center., Sch. of Med., Tohoku Univ., 3.Dept. of DGER., IDAC., Tohoku Univ.)

ConBio2017

[3P-0913（3AT26-14）] Cancer progression by cooperation of distinct oncogenic cell clones

〇Masato Enomoto^1,3, Naoki Honda², Kanami Takemoto³, Daisaku Takemoto¹, Tatsushi Igaki^1,3 (1.Lab. of Genet., Grad. Sch. of Bio., Kyoto Univ., 2.Imaging Plat., Grad. Sch. of Med., Kyoto Univ., 3.Lab. of Genet., Grad. Sch. of Pharm. Sci., Kyoto Univ.)

ConBio2017